190 related articles for article (PubMed ID: 21997981)
21. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media.
Marin D; Brancatelli G; Federle MP; Lagalla R; Catalano C; Passariello R; Midiri M; Vilgrain V
Clin Radiol; 2008 May; 63(5):577-85. PubMed ID: 18374723
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
[TBL] [Abstract][Full Text] [Related]
23. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Prokop M; Schneider G; Vanzulli A; Goyen M; Ruehm SG; Douek P; Daprà M; Pirovano G; Kirchin MA; Spinazzi A
Radiology; 2005 Feb; 234(2):399-408. PubMed ID: 15616119
[TBL] [Abstract][Full Text] [Related]
24. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
Grazioli L; Morana G; Kirchin MA; Schneider G
Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
[TBL] [Abstract][Full Text] [Related]
25. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
26. Gadolinium-enhanced MR imaging of the spleen: artifacts and potential pitfalls.
Ito K; Mitchell DG; Honjo K; Fujita T; Awaya H; Takano K; Koike S; Matsumoto T; Matsunaga N
AJR Am J Roentgenol; 1996 Nov; 167(5):1147-51. PubMed ID: 8911169
[No Abstract] [Full Text] [Related]
27. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.
Maravilla KR; Maldjian JA; Schmalfuss IM; Kuhn MJ; Bowen BC; Wippold FJ; Runge VM; Knopp MV; Kremer S; Wolansky LJ; Anzalone N; Essig M; Gustafsson L
Radiology; 2006 Aug; 240(2):389-400. PubMed ID: 16801373
[TBL] [Abstract][Full Text] [Related]
28. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
Rummeny EJ; Peters PE
Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of gadobenate dimeglumine vs gadopentetate dimeglumine in contrast- enhanced magnetic resonance imaging for diagnosis of solitary brain metastases].
Wang QJ; Wang Y; Xu X; Xiao H; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1968-73. PubMed ID: 22200693
[TBL] [Abstract][Full Text] [Related]
30. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
31. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.
Kim TK; Lee KH; Jang HJ; Haider MA; Jacks LM; Menezes RJ; Park SH; Yazdi L; Sherman M; Khalili K
Radiology; 2011 Jun; 259(3):730-8. PubMed ID: 21364083
[TBL] [Abstract][Full Text] [Related]
32. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
33. Biphasic contrast-enhanced multisection dynamic MR imaging of the liver: potential pitfalls.
Ito K; Mitchell DG; Honjo K; Fujita T; Awaya H; Matsumoto T; Matsunaga N
Radiographics; 1997; 17(3):693-705. PubMed ID: 9153706
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast.
Hylton NM
AJR Am J Roentgenol; 2003 Sep; 181(3):677-8. PubMed ID: 12933458
[No Abstract] [Full Text] [Related]
35. Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate.
Schlosser T; Hunold P; Herborn CU; Lehmkuhl H; Lind A; Massing S; Barkhausen J
Radiology; 2005 Sep; 236(3):1041-6. PubMed ID: 16055693
[TBL] [Abstract][Full Text] [Related]
36. Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging.
Yamashita Y; Hatanaka Y; Yamamoto H; Arakawa A; Matsukawa T; Miyazaki T; Takahashi M
Radiology; 1994 Oct; 193(1):59-65. PubMed ID: 8090922
[TBL] [Abstract][Full Text] [Related]
37. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions.
Mahfouz AE; Hamm B; Wolf KJ
Radiology; 1994 Jan; 190(1):49-52. PubMed ID: 8259426
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.
Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R
Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527
[TBL] [Abstract][Full Text] [Related]
40. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
